SubHero Banner

Tukysa (tucatinib) – New orphan drug approval

April 17, 2020 - The FDA announced the approval of Seattle Genetics’ Tukysa (tucatinib), in combination with trastuzumab and capecitabine, for treatment of adult patients with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Download PDF